Company intelligence / Profile preview

Atterocor, Inc.

Ann Arbor, Michigan, United Statesdnb.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 1

Overview

As of 2014, Atterocor was developing ATR-101, a novel oral drug candidate for adrenocortical carcinoma. The company started a Phase 1 human clinical trial for this rare form of cancer. Their lead compound was previously referred to as PDX in preclinical development.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecules (ATR-101, oral drug candidate)
Industry: Biotech

Drug pipeline

2 assets

ATR-101

Phase 1

Indications: Adrenal cancer, Cushing's syndrome, Congenital adrenal hyperplasia

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Atterocor, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atterocor, Inc..

Explore the full profile